Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab-afzb
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Adalimumab-afzb (PF-06410293) is a recombinant human IgG1 monoclonal antibody developed by Pfizer as a biosimilar to Humira. It functions as a tumor necrosis factor (TNF) blocker by binding specifically to TNF-alpha and neutralizing its biological activity. By blocking the interaction of TNF-alpha with the p55 and p75 cell surface TNF receptors, adalimumab-afzb inhibits the pro-inflammatory signaling cascades that drive various autoimmune and inflammatory conditions. It is administered via subcutaneous injection and is approved for the treatment of multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. In 2023, it received FDA designation as an interchangeable biosimilar.
- Brand names
- Abrilada
- Other names
- adalimumab-afzb
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on adalimumab-afzb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab-afzb.